肿瘤浸润淋巴细胞及重组白细胞介素2联合化疗在大肠癌中的应用

Postoperative use of tumor infiltrating lymphocytes and recombinant interleukin-2 in combination with chemotherapy in patients with advanced colorectal cancer

目的 研究进展期大肠癌根治术后应用肿瘤浸润淋巴细胞 (TIL)及重组白细胞介素 2(rIL 2 )联合化疗的临床治疗效果。方法 将 84例DukesB及DukesC期大肠癌患者于大肠癌根治术后采用前瞻性随机分组的方法分为 2组 :一组 44例 ,术后使用自身TIL及rIL 2联合 5 氟脲嘧啶及丝裂霉素C治疗 ;另一组 40例 ,术后单纯采用相同方案的化疗。随访 3年。结果 TIL及rIL 2联合化疗组患者 3年内局部复发率为 8% (3/ 40 ) ,化疗组为 2 7% (10 / 37) (P <0 0 5 )。TIL及rIL 2联合化疗组3年内远处转移率为 13% (5 / 40 ) ,化疗组为 35 % (13/ 37) (P <0 0 5 )。TIL及rIL 2联合化疗组 3年生存率为 90 % (36 / 40 ) ,化疗组为 73% (2 7/ 37) (P >0 0 5 )。两组的毒性反应差异无显著性。结论 对于进展期大肠癌根治术后患者 ,使用自身TIL及rIL 2联合化疗能明显降低局部复发及远处转移率 ,能提高临床治疗效果。

Objective [WT5”BZ] To evaluate the effect of tumor infiltrating lymphocytes(TIL) plus recombinant interleukin 2 (rIL 2) in combination with chemotherapy in postoperative advanced colorectal cancer patients.[WT5”HZ] Methods [WT5”BZ] Eighty four patients with colorectal cancer in Dukes B and Dukes C stage were randomized into two groups after tumor resection. Forty four patients (group A) were treated with TIL plus rIL 2 combined with 5 fluorouracil and mitomycin C. As a control, forty patients (group B) were treated only by chemotherapy.Seventy seven patients were followed up for up to three years.[WT5”HZ] Results [WT5”BZ] In group A, 8%(3/40) of the patients suffered local recurrence which was significantly lower than that in group B (27%,10/37) ( P <0 05), metastasis was found in 13% (5/40) of the patients in group A, which was significantly lower than that in group B (35%,13/37) ( P <0 05).The three year survival rate was 90% (36/40) in group A, and 73%(27/37) in group B ( P >0 05).The chemotherapy related toxicity had no significant difference between the two groups ( P >0 05).[WT5”HZ] Conclusion [WT5”BZ]The result suggested that TIL and rIL 2 combining chemotherapy can effectively enhance the clinical treatment effect of postoperative advanced colorectal cancer. [WT5”HZ]